chufangao/CTO huggingface dataset:
Clinical trial NCT03682705: A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
Official title: Rheumatoid Arthritis: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 242.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-10-08
Primary completion date: 2020-03-26
Completion date: 2020-03-26
Baseline population: Full Analysis Set: all randomized participants who received at least 1 dose of randomized study drug
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT03520946: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Official title: A Phase III Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Acronym: RAMTAS
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 430.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-24
Primary completion date: 2024-07-30
Completion date: 2024-07-30
Plan to share individual participant data: NO
IPD sharing description: No IPD will be shared
Clinical trial NCT04671901: A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
Official title: A Single Arm Open-Label Pilot Study of Prophylactic Romiplostim Use Compared to Benchmark Rate in the Prevention of Chemotherapy Induced Thrombocytopenia in Pediatric Solid Tumors Patients Undergoing Myelosuppressive Chemotherapy
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of accrual
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-10
Primary completion date: 2023-03-29
Completion date: 2023-03-29
Plan to share individual participant data: YES
IPD sharing description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT04928430: Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19
Official title: An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study
Sponsor: Xenothera SAS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Lack of recruitment
Enrollment: 290.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-28
Primary completion date: 2022-11-28
Completion date: 2022-11-28
Clinical trial NCT05569031: Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
Official title: A Comparative Study of the Efficacy of Venlafaxine and Naltrexone for Relapse Prevention in Patients With Opioid Use Disorder Attributed to Tramadol
Sponsor: Zagazig University (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-01
Primary completion date: 2021-12-15
Completion date: 2022-06-15
Plan to share individual participant data: NO
Clinical trial NCT05076149: A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
Official title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 597.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-27
Primary completion date: 2023-05-18
Completion date: 2023-11-30
Baseline population: All participants who received at least 1 dose of study drug during the treatment Period.
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT03736343: Impulsivity and Alcohol Response
Official title: Individual Differences in the Effects of Alcohol (IDEA) Study
Acronym: IDEA
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: The COVID-19 outbreak began, precluding further participant recruitment for this protocol, which could only be conducted in-person. A decision was made that ample data was available to end data collection earlier than anticipated.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-01
Primary completion date: 2020-05-31
Completion date: 2022-10-17
Plan to share individual participant data: NO
Clinical trial NCT02716038: Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Official title: A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-06-07
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Plan to share individual participant data: NO
Clinical trial NCT03665129: IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
Official title: A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors
Acronym: STELLAR-001
Sponsor: Innate Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: early termination
Enrollment: 73.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-09-07
Primary completion date: 2021-02-24
Completion date: 2021-02-24
Plan to share individual participant data: NO
Clinical trial NCT04533074: Microbiological Evaluation of Single Versus Multiple Visits Regeneration Using MALDI-TOF Mass Spectrometry
Official title: Microbiological Evaluation of Single Versus Multiple Visits Regeneration Using MALDI-TOF Mass Spectrometry (A Randomized Controlled Clinical Trial)
Sponsor: University of Alexandria (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: due to the COVID-19 pandemic
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-23
Primary completion date: 2021-03-10
Completion date: 2021-03-15
Clinical trial NCT04026880: Testosterone Effects on Pelvic Floor Muscles
Official title: A Pilot Study To Evaluate The Effect of Testosterone Enanthate On Structural and Functional Characteristics of Pelvic Floor Muscles In Postmenopausal Women With Urinary Incontinence
Acronym: TPELVIC
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Lack of funds
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-01
Primary completion date: 2022-01-01
Completion date: 2022-06-01
Plan to share individual participant data: NO
Clinical trial NCT02419170: Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
Official title: Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Investigator who manufactured the vaccine left the university.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-07-31
Primary completion date: 2019-10-31
Completion date: 2023-10-31
Clinical trial NCT04611321: Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Official title: A Phase Ib/II, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of IBI318 in Participants With Advanced Cutaneous Squamous Cell Carcinoma.
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-01
Primary completion date: 2023-03-10
Completion date: 2023-03-10
Clinical trial NCT02587598: Study of INCB053914 in Subjects With Advanced Malignancies
Official title: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Enrollment: 97.0 (ACTUAL)
Number of arms: 9.0
Start date: 2015-12-29
Primary completion date: 2020-08-11
Completion date: 2020-08-11
Clinical trial NCT03324880: A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
Official title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-24
Primary completion date: 2022-05-19
Completion date: 2022-05-19
Baseline population: Safety Analysis Set included all participants in the Intention-to-Treat (ITT) Set who took at least 1 dose of investigational product (study drug or placebo).
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT05808881: Clinical Outcomes From Nalmefene
Official title: Clinical Outcomes From Injectable Nalmefene in the Emergency Department (COINED)
Acronym: COINED
Sponsor: Purdue Pharma LP (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Due to changes in research objectives and methodological approach.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-06-30
Primary completion date: 2024-05-31
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT04095689: Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
Official title: Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL)
Acronym: INTEGRAL
Sponsor: The Methodist Hospital Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Stopping rules met per protocol, comprehensive review needed prior to enrolling again
Enrollment: 30.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2021-03-17
Primary completion date: 2024-06-30
Completion date: 2024-12-31
Clinical trial NCT05362474: Targeting Leukotrienes in Kidney Disease
Official title: Targeting Leukotrienes in Kidney Disease: A Pilot Study
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Funding not available
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-01
Primary completion date: 2023-06-20
Completion date: 2023-06-20
Plan to share individual participant data: NO
Clinical trial NCT01866111: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Official title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension
Sponsor: SK Life Science, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 437.0 (ACTUAL)
Number of arms: 4.0
Start date: 2013-07-31
Primary completion date: 2021-04-05
Completion date: 2021-10-31
Baseline population: Overall number of baseline participants includes all randomized pts, 437. Baseline analysis population includes all randomized pts who took at least 1 dose of study drug with any post-baseline seizure data (434): Pbo (n=106), Cnb: 100mg (n=108), 200mg (n=109), 400mg (n=111). Baseline seizure frequency and enrollment region used analysis population.
Clinical trial NCT03704584: Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone
Official title: Corticosteroid(CS) Injections for the Treatment of Common Upper Extremity Pathologies, With or Without Lidocaine
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment and study activities were initially suspended due to COVID-19. The investigator has also left Emory and the study will not resume.
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-14
Primary completion date: 2020-01-14
Completion date: 2020-01-14
Baseline population: 62 individuals were consented to participate, and 74 digits were randomized and injected as a part of this study. One individual with one digit withdrew from the study after injection. 61 individuals completed the study, and 73 digits are available for analysis.
Plan to share individual participant data: NO
Clinical trial NCT03536754: A Study of CCX140-B in Subjects With FSGS
Official title: A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)
Sponsor: ChemoCentryx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-05-17
Primary completion date: 2020-02-19
Completion date: 2020-02-19
Limitations and caveats: Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
Clinical trial NCT02013141: Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
Official title: An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 12 Months to 17 Years
Sponsor: Cumberland Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: FDA waived the pediatric study requirement for this application
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-12-31
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Limitations and caveats: Information on the pharmacokinetics and safety of a single dose of telavancin in subjects aged 2 to 5 years is limited as Cohort 3 only enrolled 1 participant due to early termination of the study. No infants were enrolled due to early termination of the study, and therefore, no information is available on the pharmacokinetics and safety of a single dose of telavancin in infants.
Clinical trial NCT03330704: Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation
Official title: Randomized Controlled Trial for the Use of Patient Tailored Balanced Hypertonic Solutions in Patients With Cerebral Edema
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: lack of eligible study participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-28
Primary completion date: 2020-01-01
Completion date: 2020-01-01
Plan to share individual participant data: NO
IPD sharing description: No plan to share data
Clinical trial NCT03656692: Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
Official title: A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU)
Sponsor: Mallinckrodt (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Logistical challenges; no safety concerns
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-05
Primary completion date: 2020-07-14
Completion date: 2020-07-14
Baseline population: Modified Intent to Treat population included all participants who received at least one dose of study treatment.
Plan to share individual participant data: NO
IPD sharing description: Discussion of statistical endpoints and analysis are included in manuscripts. Summary aggregate (basic) results (including adverse events information) and the study protocol are made available on clinicaltrials.gov (NCT03656692) when required by regulation. Individual de-identified patient data will not be disclosed. Requests for additional information should be directed to the company at medinfo@mnk.com.
Clinical trial NCT04665115: Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Official title: A Prospective Study of Patients With B-Cell Hematologic Malignancies on Ibrutinib Therapy Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected decline in infection rates, and the increasing use of non-ibrutinib containing BTKi therapy, we have not been able to get support for this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-23
Primary completion date: 2021-11-19
Completion date: 2022-07-22
Clinical trial NCT04461483: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants
Official title: A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Subjects
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-08-13
Primary completion date: 2020-11-14
Completion date: 2020-11-14
Baseline population: The safety analysis set included all participants who received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT03024944: TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Official title: TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Acronym: TAUPET
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: 18F-THK5351 was reported non-specific binding of MAO receptors.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-31
Primary completion date: 2019-01-31
Completion date: 2020-01-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05265728: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Official title: A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered to Japanese Participants With Relapsing-Remitting Multiple Sclerosis Via a Subcutaneous Route of Administration
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to sponsor decision, not for efficacy or safety reasons.
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-26
Primary completion date: 2024-01-18
Completion date: 2024-05-27
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/